This site is intended for health professionals only

UK launch for dexrazoxane


Dexrazoxane (Cardioxane®) has been launched in the UK for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin in advanced and/or metastatic cancer patients after previous anthracycline-containing treatment. The drug is administered by a short intravenous infusion approximately 30 minutes before anthracycline administration at a dose equal to 20 times the doxorubicin and 10 times the epirubicin-equivalent dose; this equates to a dose of 1,000mg/m2 when the commonly used dosage schedule for doxorubicin of 50mg/m2 or epirubicin 100mg/m2 is employed.

PharmaTimes 3/8/2007


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine